Literature DB >> 19107367

In vitro chemosensitivity testing of primary and recurrent breast carcinomas and its clinical significance.

Zhi Li1, Haiping Song, Wenshan He, Yuan Tian, Tao Huang.   

Abstract

In this study, in vitro chemosensitivity testing was conducted on primary cultured breast cancer cells from 96 patients with breast cancer, and the results showed that the cells from a few patients with primary breast cancer developed multidrug resistance (MDR) prior to the first chemotherapy exposure. All the cells from the recurrent cancer patients had MDR. The findings suggested that patients having MDR would benefit from high-dose chemotherapy (HDC) regimens. In vitro chemosensitivity screening, which was aimed at improving the therapeutic efficacy and minimizing side effects, helps in choosing individualized treatment for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19107367     DOI: 10.1007/s11596-008-0616-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  33 in total

1.  Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment.

Authors:  C S Thomson; D H Brewster; J A Dewar; C J Twelves
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

Review 2.  High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer.

Authors:  P Pedrazzoli; E Tarenzi; C Tullio; G Colosini; S Siena
Journal:  J Chemother       Date:  2004-11       Impact factor: 1.714

3.  Trastuzumab in breast cancer.

Authors:  Stuart G Gilbert
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

4.  Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling.

Authors:  Lisa J Frederiksen; Richard Sullivan; Lori R Maxwell; Shannyn K Macdonald-Goodfellow; Michael A Adams; Brian M Bennett; D Robert Siemens; Charles H Graham
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 5.  Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.

Authors:  George Lazaridis; George Pentheroudakis; Nicholas Pavlidis
Journal:  Crit Rev Oncol Hematol       Date:  2007-09-04       Impact factor: 6.312

Review 6.  Roles of multidrug resistance genes in breast cancer chemoresistance.

Authors:  M Tien Kuo
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

7.  High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

Authors:  Sjoerd Rodenhuis; Marijke Bontenbal; Louk V A M Beex; John Wagstaff; Dick J Richel; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Harm van Tinteren; Hans L Peterse; Elisabeth M TenVergert; Elisabeth G E de Vries
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

Review 8.  MDR1, chemotherapy and chromatin remodeling.

Authors:  Emma K Baker; Assam El-Osta
Journal:  Cancer Biol Ther       Date:  2004-09-23       Impact factor: 4.742

9.  Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.

Authors:  Alejandro Vazquez-Martin; Ramon Colomer; Joan Brunet; Javier A Menendez
Journal:  Int J Oncol       Date:  2007-10       Impact factor: 5.650

Review 10.  The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).

Authors:  L J A Hardwick; S Velamakanni; H W van Veen
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.